| Ytd | -67.21% | |
| 1y | -86.53% |
| Open | 0.29 | Prev Close | 0.29 | Low | 0.29 | High | 0.30 | Mkt Cap | 4.64M |
| Vol | 298.13K | Avg Vol | 2.23M | EPS | -3.11 | P/E | N/A | Forward P/E | -9.08 |
| Beta | 0.64 | Short Ratio | 0.12 | Inst. Own | 22.26% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 0.32 | 200-d Avg | 1.03 | 1yr Est | 102.00 |
Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-sta
~ ~ Advances First-in-Class, Breakthrough Therapy-Designated Opioid Engineered to Protect Against Or
https://data.epo.org/publication-server/publications/pdf?path=2026/21/DOC/EPNWB1/EP20767314NWB1/EP20
https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_05182026_ENSC_Sorensen.pdf
Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(0.52) per share which beat the anal
The patent, titled "Compositions Comprising Enzyme-Cleavable Prodrugs and Controlled Release Naf
US stocks traded lower, Dow down 600 points. Nasdaq and S&P also fell. Consumer staples up, tech